Sacubitril: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 2: | Line 2: | ||
Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also [https://en.wikipedia.org/wiki/Sacubitril Sacubitril]. | Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also [https://en.wikipedia.org/wiki/Sacubitril Sacubitril]. | ||
Sacubitril is a prodrug that is activated to sacubitrilat (LBQ657) by de-ethylation via esterases.[ | Sacubitril is a prodrug that is activated to sacubitrilat (LBQ657) by de-ethylation via esterases.<ref name="a2">Solomon SD. [https://esc365.escardio.org/home "HFpEF in the Future: New Diagnostic Techniques and Treatments in the Pipeline".] Boston. p. 48. Retrieved 2012-01-26</ref> Sacubitrilat inhibits the enzyme neprilysin,<ref name="a3">PMID:28438180</ref> which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure–lowering peptides that work mainly by reducing blood volume.<ref name="a4">PMID:28438180</ref> | ||
<scene name='10/1001143/Overall/1'>NEPRILYSIN COMPLEXED WITH Sacubitrilat</scene> ([[5jmy]]). | <scene name='10/1001143/Overall/1'>NEPRILYSIN COMPLEXED WITH Sacubitrilat</scene> ([[5jmy]]). | ||
Revision as of 13:00, 16 October 2023
Sacubitril is an antihypertensive drug used in combination with valsartan. The combination drug sacubitril/valsartan, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. See also Sacubitril. Sacubitril is a prodrug that is activated to sacubitrilat (LBQ657) by de-ethylation via esterases.[1] Sacubitrilat inhibits the enzyme neprilysin,[2] which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure–lowering peptides that work mainly by reducing blood volume.[3] (5jmy). . Water molecules are shown as red spheres. .
|
| ||||||||||
ReferencesReferences
- ↑ Solomon SD. "HFpEF in the Future: New Diagnostic Techniques and Treatments in the Pipeline". Boston. p. 48. Retrieved 2012-01-26
- ↑ Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, Wu K. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017 Apr 24;10(1):97. PMID:28438180 doi:10.1186/s13045-017-0467-2
- ↑ Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, Wu K. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. J Hematol Oncol. 2017 Apr 24;10(1):97. PMID:28438180 doi:10.1186/s13045-017-0467-2